- Home
- ODD vs MLYS Comparison
ODD vs MLYS Comparison
Compare ODD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- MLYS
- Stock Information
- Founded
- ODD 2018
- MLYS 2019
- Country
- ODD Israel
- MLYS United States
- Employees
- ODD N/A
- MLYS N/A
- Industry
- ODD
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- MLYS Health Care
- Exchange
- ODD Nasdaq
- MLYS Nasdaq
- Market Cap
- ODD 3.8B
- MLYS 3.1B
- IPO Year
- ODD 2023
- MLYS 2023
- Fundamental
- Price
- ODD $45.80
- MLYS $40.00
- Analyst Decision
- ODD Buy
- MLYS Strong Buy
- Analyst Count
- ODD 11
- MLYS 6
- Target Price
- ODD $75.36
- MLYS $42.60
- AVG Volume (30 Days)
- ODD 651.0K
- MLYS 1.3M
- Earning Date
- ODD 11-19-2025
- MLYS 11-10-2025
- Dividend Yield
- ODD N/A
- MLYS N/A
- EPS Growth
- ODD 25.95
- MLYS N/A
- EPS
- ODD 1.80
- MLYS N/A
- Revenue
- ODD $751,854,000.00
- MLYS N/A
- Revenue This Year
- ODD $25.43
- MLYS N/A
- Revenue Next Year
- ODD $20.18
- MLYS N/A
- P/E Ratio
- ODD $25.47
- MLYS N/A
- Revenue Growth
- ODD 26.12
- MLYS N/A
- 52 Week Low
- ODD $35.30
- MLYS $8.24
- 52 Week High
- ODD $79.18
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- ODD 23.41
- MLYS 53.93
- Support Level
- ODD $49.17
- MLYS $41.74
- Resistance Level
- ODD $52.00
- MLYS $44.60
- Average True Range (ATR)
- ODD 2.33
- MLYS 2.22
- MACD
- ODD -0.57
- MLYS -0.83
- Stochastic Oscillator
- ODD 1.11
- MLYS 46.44
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.